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ABSTRACT
Objective To assess trends in systolic blood pressure 
(SBP) thresholds at initiation of antihypertensive treatment 
in patients with type 2 diabetes and the impact of age and 
frailty on these trends.
Study design and setting A repeated cross- sectional 
cohort study (2007–2014) using the Groningen Initiative 
to Analyse Type 2 diabetes Treatment database was 
conducted. The influence of calendar year, age or frailty 
and the interaction between year and age or frailty on 
SBP thresholds were assessed using multilevel regression 
analyses adjusted for potential confounders.
Results We included 4819 patients. The mean SBP at 
treatment initiation was 157 mm Hg in 2007, rising to 
158 mm Hg in 2009 and decreasing to 151 mm Hg in 
2014. This quadratic trend was significant (p<0.001). 
Older patients initiated treatment at higher SBP, but 
similar decreasing trends after 2009 were observed in all 
age groups. There were no significant differences in SBP 
thresholds between patients with different frailty groups. 
The association between year and SBP threshold was not 
influenced by age or frailty.
Conclusion After an initial rise, the observed SBP 
thresholds decreased over time and were not influenced 
by age or frailty. This is in contrast with changed guideline 
recommendations towards more personalised treatment 
during the study period and illustrates that changing 
prescribing practice may take considerable time. Patient- 
specific algorithms and tools focusing on when and 
when not to initiate treatment could be helpful to support 
personalised diabetes care.
INTRODUCTION
Treatment of hypertension in patients with 
type 2 diabetes (T2D) reduces cardiovas-
cular risk, but guideline recommendations 
on when to initiate antihypertensive treat-
ment to best balance the benefits and risks 
of treatment have changed over time. In the 
past, the recommended systolic blood pres-
sure (SBP) threshold for treatment initiation 
ranged from 130 mm Hg to 140 mm Hg.1–7 
A personalised approach, however, has been 
advocated in the last decade for older and/
or frail patients, who are at increased risk of 
adverse outcomes related to low blood pres-
sure (BP) levels.4 6 7 Since 2011, treatment 
guidelines started to recommend higher SBP 
thresholds in these patients (figure 1).3–11 
A recent interview study showed that Dutch 
general practitioners were indeed somewhat 
reluctant to initiate antihypertensive treat-
ment in older and/or frail patients.12 Studies 
showing at which SBP thresholds physicians 
initiate antihypertensive treatment in older 
or frail patients are lacking.
A Danish study observed an average SBP 
level in the general population of 148 mm 
Hg before they received antihypertensive 
treatment in the period from 1976 to 2004.13 
Trend studies on antihypertensive medica-
tion use and hypertension control in indi-
viduals with T2D show that the percentage 
of people achieving the recommended 
Strengths and limitations of this study
 ► This is a first study investigating trends in systolic 
blood pressure thresholds at initiation of antihyper-
tensive treatment in patients with type 2 diabetes.
 ► Real- world data from primary care of a large num-
ber of patients with type 2 diabetes initiating antihy-
pertensive treatment were used.
 ► The analyses were adjusted for a range of possible 
confounders and multiple imputation was used to 
reduce any possible bias that could have occurred 
due to missing data.
 ► The number of included general practices and pa-
tients fluctuated over the years.
 ► Frailty might have been underestimated due to in-
complete recording of International Classification of 
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SBP target of <140 mm Hg increased over the last 20 
years.14 15 An observational study conducted in the Neth-
erlands showed that the mean achieved SBP decreased 
from 155 mm Hg in 1998 to 140 mm Hg in 2008 in all age 
groups, with a mean SBP being lower in younger patients. 
No relevant differences in trends were observed between 
different age groups.16 This indicates that BP control in 
patients with T2D has generally improved over time. The 
extent to which the more recent personalised guideline 
recommendations are followed, however, is not clear. This 
may depend on physician or practice characteristics,17 18 
resulting in variability between treatment decisions.19
The aim of this study was to assess trends in SBP thresh-
olds for initiating antihypertensive medication in patients 
with T2D and the impact of changed treatment recom-
mendations for older and frail patients. We looked at the 
period between 2007 and 2014, for which we hypothe-
sised that SBP thresholds would remain similar among 
young and non- frail patients but would increase among 
older and/or frail patients. Our secondary aim was to 
assess to what extent SBP thresholds for treatment initia-
tion varied across general practices.
METHODS
Study design and population
This was a repeated cross- sectional dynamic cohort study 
for the years 2007–2014. The Groningen Initiative to 
Analyse Type 2 diabetes Treatment ( www. giantt. nl) data-
base was used, which contains anonymous electronic 
medical records data of patients with T2D treated in 
primary care in the north of the Netherlands.
Patients were included per calendar year when they 
had a diagnosis of T2D and were ≥18 years. We excluded 
patients who were not included in the database for at 
least 365 days before antihypertensive treatment initi-
ation and did not initiate treatment with an antihyper-
tensive (Anatomical Therapeutic Chemical codes C03, 
C04, C07, C08, C09) in that year. Antihypertensive treat-
ment initiation was defined as an initial prescription 
without a prescription of any antihypertensive drug in the 
preceding 365 days. Furthermore, patients were excluded 
when they did not have a documented SBP level within 
120 days before or at the day of treatment initiation or 
when they initiated treatment with three or more drug 
classes, since it is unlikely that this was a true initiation. 
It is assumed that these are patients with prevalent anti-
hypertensive treatment, who entered the dynamic cohort 
during the study period. Moreover, we excluded patients 
initiating propranolol or a loop diuretic (furosemide, 
bumetanide), since these are commonly prescribed for 
other indications (ie, migraine prophylaxis or short- term 
use in patients with oedema, respectively). No approval 
from an ethics committee is needed for studies using data 
from anonymous medical records in the Netherlands. An 
exemption letter from University Medical Center Gron-
ingen Medical Ethics Review Board was obtained (refer-
ence number M19.235285).
Outcome variable
The outcome was the patient’s most recent office SBP 
level in the 120 days before or on the day of antihyperten-
sive treatment initiation.
Explanatory variables
The following explanatory variables were included: 
calendar year, age or frailty of the patient and the inter-
action between year and age or frailty. Age was calculated 
Figure 1 American, European and Dutch guideline recommended systolic blood pressure values for initiation of 
antihypertensive treatment in patients with type 2 diabetes over the years (1=American College of Cardiology/American Heart 
Association (ACC/AHA) guidelines8; 2=ACC/AHA Expert Consensus Document on Hypertension in the Elderly4; 3=American 
Diabetes Association (ADA) Standards of Medical Care in Diabetes3 9; 4=European Society of Cardiology/Euro Heart Care 
(ESC/EHC) guidelines for hypertension management5 6 10; 5=Dutch College of General Practitioners (NHG) cardiovascular risk 
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on 1 January of each year and was categorised in four 
groups (<60 years, 60–69 years, 70–79 years and ≥80 years) 
related to cut- off values mentioned in several guide-
lines.7 11 20 Frailty was calculated using a previously devel-
oped electronic Frailty Index (eFI), which is based on 
140 International Classification of Primary Care (ICPC) 
coded symptoms and diagnoses from the medical history 
as well as the existence of polypharmacy.21 These ICPC 
codes are grouped into 36 deficits, for which patients 
get points. For chronic conditions, a diagnostic code 
anytime in the past is included, whereas for short- term or 
episodic conditions only diagnostic codes from the past 
year are included. The sum of the points from the deficits 
divided by 36 is the indication of frailty and can take a 
value between 0 (patient has no deficits) and 1 (patient 
has all possible deficits). Since all included patients had 
diabetes, we excluded diabetes from the eFI, thus focusing 
on additional frailty. There are no validated clinical cut- 
off values for the eFI; therefore, we categorised the scores 
in tertiles based on the eFI values in our study population 
to compare less, medium and more frail patients.
Confounders
The following patient characteristics were included as 
possible confounders: sex, diabetes duration (<2 years or 
≥2 years), presence of dyslipidaemia (low density choles-
terol (LDL) ≥2.5 mmol/L), glycated haemoglobin level 
(HbA1c <7% or ≥7%), estimated glomerular filtration 
rate (eGFR; ≤60 mL/min or >60 mL/min), presence of 
elevated albuminuria (albumin creatinine ratio ≥30 mg/g 
or albumin in 24 hours urine ≥300 mg), history of cardio-
vascular events (presence yes/no of myocardial disease, 
heart failure or stroke), body mass index (BMI; <24.9 kg/
m2, 25–29.9 kg/m2 or ≥30 kg/m2), number of prescribed 
chronic medication (continuous variable), number and 
type of glucose lowering treatment (none, one oral, 
two oral, three or more oral and/or insulin) and lipid 
lowering treatment (none or one/more drug classes). 
The most recent laboratory values available in the 365 
days before or 7 days after treatment initiation were used. 
BMI was calculated from weight and height or extracted 
from the database in case these were not available. The 
eGFR was calculated from serum creatinine using the 
Modification of Diet in Renal Disease-4 equation for 
the years 2007–2009, and using the Chronic Kidney 
Disease Epidemiology Collaboration equation from 2010 
onwards, since the standard way of calculating eGFR in 
the Netherlands changed during the study period.22 In 
case serum creatinine was not available, the eGFR was 
extracted from the database when available. Prescribed 
medication was assessed in the 120 days before or at the 
day of treatment initiation.
Missing data
There were no missing data for the explanatory variables. 
Values of confounders with <20% of missing values were 
imputed using multiple imputation by chained equation. 
23 For patients without albuminuria measurements (47%), 
we assumed that they did not have elevated albuminuria, 
since urine samples were less likely to be collected in our 
study period for patients without suspected renal func-
tion problems.
Analyses
Descriptive statistics were performed to examine patient 
characteristics per calendar year.
We conducted multilevel regression analyses with a 
two- level random intercept model to account for patients 
being nested within general practices. First, using the 
empty model, which includes only the outcome vari-
able, we calculated the intraclass correlation coefficient 
to assess the variance that is attributed to general prac-
tices. Second, we added the confounders to assess the 
overall trend over the years. We compared a linear and 
a quadratic model using the Wald test to choose the best 
fitting final model. In the final model, we assessed the 
effect of age or frailty on the trends by adding the explan-
atory variables and the interaction between year and age 
or frailty on SBP levels at treatment initiation.
Additional subgroup analyses were conducted for each 
age and frailty group to assess changes over time in these 
subpopulations using the final model. After applying 
Bonferroni correction for multiple testing, significance 
levels were set at p<0.0125 (per age group) and p<0.0167 
(per frailty group).
Furthermore, we conducted sensitivity analyses using 
the average of the last two SBP levels instead of a single 
SBP measurement and using eFI as a continuous variable 
in the final model.
The analyses were conducted in Stata V.14 (Stata Corp.).
Patient and public involvement
Patients and public were not involved in this study.
RESULTS
A total of 4819 patients initiating antihypertensive treat-
ment in the period 2007–2014 were included (table 1). 
A flow chart of excluded patients per calendar year is 
presented in online supplementary figure 1. Patient char-
acteristics were generally similar throughout the years 
(online supplementary table 1). Seventy- four per cent of 
included patients had no missing values.
Trends in SBP thresholds
The mean SBP level at antihypertensive treatment initi-
ation significantly changed over time from 157 mm Hg 
(SD 22 mm Hg) in 2007, rising to 158 mm Hg (SD 21 mm 
Hg) in 2009 and thereafter decreasing to 151 mm Hg (SD 
22 mm Hg) in 2014 (figure 2A). This quadratic trend was 
statistically significant (p<0.001).
Age and frailty
Older patients initiated treatment at significantly higher 
SBP thresholds than younger patients but age did not 
significantly influence the relationship between calendar 
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per age group, the SBP level at initiation changed signifi-
cantly (quadratic model) over the years in patients aged 
between 60 and 69 years (p=0.001).
Frailty did not influence SBP thresholds for treatment 
initiation and it did not significantly influence the relation-
ship between calendar year and SBP threshold (table 2, 
figure 2C). In the analyses per frailty group, the SBP level 
at initiation changed significantly (quadratic model) over 
the years in the less frail (eFI 0–0.03; p<0.001) and more 
frail (eFI 0.11–0.40; p=0.001) patients.
The sensitivity analyses using the mean of the last two 
SBP levels (online supplementary figure 2A- C and online 
supplementary table 2) and using eFI as a continuous 
variable (online supplementary table 3) showed similar 
results.
Variation between general practices
Of the total variation in SBP level at antihypertensive treat-
ment initiation, 3.2% could be explained by differences 




This study shows that, after an initial rise up to 2009, 
SBP thresholds for antihypertensive treatment initiation 
decreased over time in a large cohort of patients with T2D 
treated in primary care. This trend occurred regardless of 
age and frailty, which was in contrast to our hypothesis 











Females; N (%) 2259 (47)





Frailty in electronic Frailty Index 
score; N (%)
  
Less frail: 0–0.03 2070 (43)
Medium frail: 0.06–0.09 1628 (34)
More frail: 0.11–0.40 1121 (23)
Systolic BP at initiation in mm Hg; 
mean±SD
155±22
Diastolic BP at initiation in mm Hg; 
mean±SD
85±12
Diabetes duration <2 years; N (%) 1259 (26)
HbA1c<7%; N (%)* 2717 (61)




Dyslipidaemia; N (%)‡ 2263 (57)
eGFR ≤60 mL/min/1.73m2; N (%)§ 542 (13)
Elevated albuminuria (%)¶ 101 (4)
History of cardiovascular disease; N 
(%)
Myocardial disease** 263 (5)
Heart failure†† 90 (2)
Stroke‡‡ 212 (4)
Number of chronic medication at 
initiation; mean±SD
3.6±2.5
Glucose lowering medication at 
initiation; N (%)
  
No medication 1269 (26)
1 oral 1937 (40)
2 oral 982 (21)
3 oral or more and/or insulin 631 (13)
Continued
Included patients
Treated with a lipid lowering drug; N 
(%)
2749 (57)





Beta blocker 689 (14)
Calcium channel blocker 240 (5)
Combination of antihypertensives 474 (10)
*Haemoglobin A1C (HbA1c): 352 (7.3 %) missing values.
†Body mass index (BMI): 427 (8.9 %) missing values.
‡LDL cholesterol: 874 (18.1%) missing values.
§Estimated glomerular filtration rate (eGFR): 677 (14.0 %) missing 
values.
¶Albuminuria: 2274 (47.2%) missing values.
**Acute myocardial infarction (ICPC code K75) in the last year or 
other/chronic ischaemic heart disease (ICPC code K76) anytime in 
history.
††Heart failure (ICPC code K77) anytime in history.
‡‡Transient cerebral ischaemia (ICPC code K89) in the last year 
or stroke/cerebrovascular incident (ICPC code K90) anytime in 
history.
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given the changes in guideline recommendations. The 
variation in SBP thresholds for treatment initiation that 
could be attributed to general practices was small.
Strengths and limitations
The strength of our study is the large number of 
patients included using real- world data. Furthermore, it 
is a first study investigating trends in SBP thresholds at 
initiation of antihypertensive treatment. We focused on 
the period from 2007 to 2014, expecting that the shift 
towards more personalised diabetes care around 2011 
could be observed during this period. It is possible that 
changes occurred in more recent years. The first limita-
tion is the fluctuating number of general practices over 
the years, with different numbers of patients and prac-
tices included in each year cohort. Since little variation 
was explained at practice level, it is unlikely that this 
affected our primary findings. Second, there were some 
demographic differences between the patients with and 
without missing data (online supplementary table 4). 
This bias was reduced by multiple imputation.24 Third, 
we could not include smoking or date of hypertension 
diagnosis as confounders due to amount and variability 
of missing values over the years. Furthermore, ICPC 
codes do not provide information about the severity 
of the comorbidities. Therefore, there may be some 
residual confounding which was not accounted for. 
Fourth, incomplete coding of ICPC diagnoses in elec-
tronic medical records may result in underestimation of 
frailty. Finally, SBP levels show intraindividual variability 
and may include higher values caused by ‘white coat’ 
hypertension.25 However, analysis of the mean last two 
SBP levels did not change our main findings.
Comparison with existing literature
The observed trends are not in line with changes in 
treatment guidelines, where higher thresholds were 
recommended in the older and/or frail patients, partic-
ularly in the later years. Several reasons can explain this 
discrepancy between our hypothesis and findings. First, 
Dutch healthcare practitioners may have felt pressured 
to initiate antihypertensive treatment at lower SBP levels 
in all patients with diabetes after the introduction of 
performance indicators in 2007.26 From 2008 onwards, 
they received yearly feedback on the percentage of 
patients achieving SBP levels of <140 mm Hg in their 
own practice as compared with other practices in the 
region. Although a previous study in this population 
did not show an increase in overtreatment after the 
introduction of performance indicators,27 concerns 
about the negative impact of such measures have been 
raised.28 In addition, nurse practitioners increasingly 
became the pivot of diabetes care26 and their educa-
tional material recommended a unified SBP target of 
140 mm Hg at least until the end of our study period.29 
It is also possible that the practitioners did not adhere 
to treatment guidelines either due to lack of famil-
iarity, understanding or agreement with them.30–32 An 
interview study conducted in 2015 and 2016, however, 
suggests that Dutch general practitioners did support 
the idea of using a higher threshold for initiation of 
antihypertensive treatment in older and frail patients.12 
Nevertheless, we demonstrated that guideline changes 
were not yet implemented more than 3 years after being 
published.
Figure 2 Mean last systolic blood pressure (BP) value 
with 95% CIs before/at antihypertensive treatment initiation 
(A) through the years; (B) through the years in different age 
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Antihypertensive treatment was initiated at relatively 
high SBP levels in patients of all ages but started to 
decline after 2009, suggesting that it took many years 
before the United Kingdom Prospective Diabetes Study 
recommended threshold of 140 mm Hg for treatment 
initiation was implemented in practice.2 Other studies 
showed that the percentage of patients achieving an SBP 
<140 mm Hg increased in the last two decades but that 
this increase was smaller in older patients.15 A recent US 
study showed that the trends in SBP levels in patients 
≥60 years decreased until 2010 and remained relatively 
stable in the 6 years thereafter.33 Although this study was 
not restricted to patients with T2D, this seems in contrast 
with our findings where SBP levels after 2009 decreased 
in all age groups.
To our surprise, frailty did not influence the SBP 
threshold for treatment initiation. The frailty range in 
our study was rather low, which could indicate that anti-
hypertensive treatment is initiated when the patients are 
still relatively fit. On the other hand, frailty can easily be 
overlooked due to subtle manifestations, lack of time or a 
lack of consensus on the best way to assess it.34 Although 
the eFI was previously able to identify frailty comparable 
to the Groningen Frailty Index,21 it might not be in line 
with the practitioner’s perception of a patient’s frailty. 
Therefore, we conducted a post- hoc analysis using the 
number of chronic medication a patient was receiving 
at initiation as a proxy for frailty. We observed that the 
patients being treated with more than three chronic 
medication (median) initiated treatment at lower SBP 
levels than those being treated with three or less (online 
supplementary figure 3 and online supplementary table 
5). This finding suggests that lower instead of higher 
thresholds are used for frail patients.
Only a small part of the variation in our study could be 
attributed to differences between practices. This suggests 
that patient characteristics determine the threshold to 
a greater extent than practice characteristics. We only 
looked at variation between practices which may include 
decisions of two or more general practitioners within one 
practice. Unfortunately, we could not conduct analyses at 
the level of individual practitioners.
CONCLUSION AND IMPLICATIONS
The observed SBP thresholds at initiation of antihy-
pertensive treatment decreased after 2009. This trend 
was not influenced by age or frailty, which is in contrast 
with changes in treatment recommendations, and may 
be explained by the introduction of performance indi-
cators. Our study illustrates that changing prescribing 
practice may take considerable time and only publishing 
new recommendations might not be sufficient for their 
successful implementation. On one hand, patient- 
specific algorithms and tools to support the timely 
start of antihypertensive treatment in younger patients 
are needed. On the other hand, also algorithms and 
tools to prevent the initiation of too early or strict 
Table 2 Influence of calendar year and age or frailty on blood pressure thresholds (multilevel analysis)
β 95% CI P value
Age*   
Calendar year −0.107 −1.429 to 1.215 0.874 <0.001†
Calendar year2 −0.111 −0.248 to 0.027 0.114
Age <60 years −8.066 −10.411 to −5.723 <0.001
Age 60–69 years −4.115 −6.369 to −1.861 <0.001
Age 70–79 years −1.168 −3.407 to 1.072 0.307
Age ≥80 years Reference group
Interaction year* age None are significant
Frailty‡   
Calendar year 0.247 −1.100 to 1.593 0.719 <0.001†
Calendar year2 −0.159 −0.299 to 0.018 0.027
Frailty 0–0.03 −0.060 −1.734 to 1.614 0.944
Frailty 0.06–0.09 0.127 −1.519 to 1.772 0.880
Frailty 0.11–0.40 Reference group
Interaction year* frailty None are significant
The intraclass correlation coefficient calculated from the empty model was 0.032.
*The age model was adjusted for sex, duration of diabetes, number of chronic medication at initiation, number and/or type of glucose 
lowering therapy, lipid lowering therapy, presence of albuminuria, presence of dyslipidaemia, haemoglobin A1C (HbA1c), history of 
cardiovascular events, estimated glomerular filtration rate and body mass index.
†Joined significance of calendar year and calendar year2 using the Wald test.
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antihypertensive treatment in older and frail patients 
should be developed. Furthermore, performance 
indicators should include the aspect of more person-
alised treatment recommendations. Further research 
is needed to assess the underlying reasons and extent 
of the delay in the implementation of personalised 
diabetes care and evaluate the impact of strategies to 
speed up the uptake of recommendations.
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